DE19721700C1 - Mutierter OKT3-Antikörper - Google Patents

Mutierter OKT3-Antikörper

Info

Publication number
DE19721700C1
DE19721700C1 DE19721700A DE19721700A DE19721700C1 DE 19721700 C1 DE19721700 C1 DE 19721700C1 DE 19721700 A DE19721700 A DE 19721700A DE 19721700 A DE19721700 A DE 19721700A DE 19721700 C1 DE19721700 C1 DE 19721700C1
Authority
DE
Germany
Prior art keywords
monoclonal antibody
okt3
expression
vector
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE19721700A
Other languages
German (de)
English (en)
Inventor
Sergey Dr Kipriyanov
Melvyn Prof Dr Little
Gerhard Dr Moldenhauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to DE19721700A priority Critical patent/DE19721700C1/de
Priority to EP98934774A priority patent/EP0983302B1/de
Priority to PCT/DE1998/001409 priority patent/WO1998052975A1/de
Priority to AT98934774T priority patent/ATE324381T1/de
Priority to DE59813519T priority patent/DE59813519D1/de
Priority to ES98934774T priority patent/ES2263212T3/es
Priority to JP54981698A priority patent/JP4276302B2/ja
Application granted granted Critical
Publication of DE19721700C1 publication Critical patent/DE19721700C1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE19721700A 1997-05-23 1997-05-23 Mutierter OKT3-Antikörper Expired - Fee Related DE19721700C1 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE19721700A DE19721700C1 (de) 1997-05-23 1997-05-23 Mutierter OKT3-Antikörper
EP98934774A EP0983302B1 (de) 1997-05-23 1998-05-22 Mutiertes ScFv-Fragment des OKT-3 Antikörpers
PCT/DE1998/001409 WO1998052975A1 (de) 1997-05-23 1998-05-22 Mutierter okt3-antikörper
AT98934774T ATE324381T1 (de) 1997-05-23 1998-05-22 Mutiertes scfv-fragment des okt-3 antikörpers
DE59813519T DE59813519D1 (de) 1997-05-23 1998-05-22 Mutiertes ScFv-Fragment des OKT-3 Antikörpers
ES98934774T ES2263212T3 (es) 1997-05-23 1998-05-22 Anticuerpo okt3 mutado.
JP54981698A JP4276302B2 (ja) 1997-05-23 1998-05-22 突然変異させたｏｋｔ３抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19721700A DE19721700C1 (de) 1997-05-23 1997-05-23 Mutierter OKT3-Antikörper

Publications (1)

Publication Number Publication Date
DE19721700C1 true DE19721700C1 (de) 1998-11-19

Family

ID=7830336

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19721700A Expired - Fee Related DE19721700C1 (de) 1997-05-23 1997-05-23 Mutierter OKT3-Antikörper
DE59813519T Expired - Lifetime DE59813519D1 (de) 1997-05-23 1998-05-22 Mutiertes ScFv-Fragment des OKT-3 Antikörpers

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59813519T Expired - Lifetime DE59813519D1 (de) 1997-05-23 1998-05-22 Mutiertes ScFv-Fragment des OKT-3 Antikörpers

Country Status (6)

Country Link
EP (1) EP0983302B1 (OSRAM)
JP (1) JP4276302B2 (OSRAM)
AT (1) ATE324381T1 (OSRAM)
DE (2) DE19721700C1 (OSRAM)
ES (1) ES2263212T3 (OSRAM)
WO (1) WO1998052975A1 (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
HUE029925T2 (en) 2008-04-02 2017-04-28 Macrogenics Inc HER2 / neu-specific antibodies and methods using them
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
EP2895203A4 (en) * 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP6815196B2 (ja) 2013-03-13 2021-01-20 イマジナブ、 インコーポレイテッド Ｃｄ８に対する抗原結合性構築物
CN111925437A (zh) 2013-03-14 2020-11-13 宏观基因有限公司 与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
EP3812398A3 (en) 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
KR20250008141A (ko) 2015-08-07 2025-01-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hum. Antibod. Hybridomas, 1994, Vol. 5, 1 und 2, S. 41-47 *

Also Published As

Publication number Publication date
DE59813519D1 (de) 2006-06-01
JP4276302B2 (ja) 2009-06-10
ES2263212T3 (es) 2006-12-01
EP0983302A1 (de) 2000-03-08
ATE324381T1 (de) 2006-05-15
EP0983302B1 (de) 2006-04-26
JP2001527414A (ja) 2001-12-25
WO1998052975A1 (de) 1998-11-26

Similar Documents

Publication Publication Date Title
EP0983302B1 (de) Mutiertes ScFv-Fragment des OKT-3 Antikörpers
DE60127143T2 (de) Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
DE19819846B4 (de) Multivalente Antikörper-Konstrukte
DE69434578T2 (de) Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteinen in Zellen von Säugetieren
DE69133179T2 (de) Katalytische antikörperkomponente
US5939531A (en) Recombinant antibodies specific for a growth factor receptor
EP1566442B1 (de) Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")
DE60124912T2 (de) Multimerische, einzelkettige, Tandem-Fv-Antikörper
DE60133479T2 (de) Modifizierter tpo-agonisten antikörper
DE69406423T2 (de) Methode zum überbringen von agenzien an zielzellen
DE102010039018B4 (de) Anti-La Antikörper und ihre Anwendung zum Immunotargeting
DE102011118022A1 (de) Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
DE69634774T2 (de) Modulatoren von regulationsproteinen
CN104098698A (zh) 一种抗cd3抗体及其制法和应用
George et al. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule.
DE60118370T2 (de) Leader-anteile zur erhöhung der sekretion von rekombinanten proteinen aus einer wirtzelle
DE60214127T2 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
EP0720623B1 (de) Monoklonale antikörper gegen leukozyten-spezifische g-protein-gekoppelte rezeptoren
DE69020112T2 (de) Spezifische bindende Wirkstoffe.
DE69216600T2 (de) Synthetisches CDw52(CAMPATH-1) Peptidantigen
EP1141271A1 (de) Selektion von monoklonalen antikörpern
WO2001027159A2 (de) Polypeptide zur detektion und elimination ca19-9 antigen positiver zellen
JP2020534023A (ja) ｈＥＲＧ１およびｈＥＲＧ１／インテグリンβ１に結合する単一特異性および二重特異性抗体
EP1015583B1 (de) Srcr domäne-enthaltendes protein
EP1092769B1 (de) Polypeptid-Tag's für den Nachweis und die Aufreinigung von Polypeptiden

Legal Events

Date Code Title Description
8100 Publication of patent without earlier publication of application
D1 Grant (no unexamined application published) patent law 81
8364 No opposition during term of opposition
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20111201